E69 476
Acknowledgments:
The authors thank Daniel Laajala for his expert
comments. This work was supported by the Academy of Finland (grants
292611, 269862, 272437, 279163, 295504, and 268531), the National
Cancer Institute (16X064), the Finnish Medical Foundation, and the
Cancer Society of Finland.
References
[1]
Seyednasrollah F, Mahmoudian M,[16_TD$DIFF]
Rautakorpi L, et al. How reliable are trial-based prognostic models in real-world patients with met- astatic castration-resistant prostate cancer? Eur Urol 2017;[17_TD$DIFF]
71: 838–40.
[2]
Guinney J, Wang T, Laajala TD, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol 2017;18: 132–42.
Tuomas Mirtti
a,b
Tero Aittokallio
a,c,
*
a
Institute for Molecular Medicine Finland, University of Helsinki,
Helsinki, Finland
b
Department of Pathology, Helsinki University Hospital,
Helsinki, Finland
c
Department of Mathematics and Statistics, University of Turku,
Turku, Finland
*Corresponding author. Institute for Molecular Medicine Finland,
Nordic EMBL Partnership for Molecular Medicine,
Biomedicum Helsinki 2U, P.O. Box 20, Tukholmankatu 8,
Helsinki FI-00014, Finland. Tel. +358 503182426.
E-mail address:
tero.aittokallio@helsinki.fi(T. Aittokallio).
April 24, 2017
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 6 8 – e 6 9
e69